{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:04:31Z","timestamp":1785503071860,"version":"3.56.0"},"reference-count":43,"publisher":"Akademiai Kiado Zrt.","issue":"14","license":[{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis Egyetem","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,4,5]]},"abstract":"<jats:p>A rosszindulat\u00fa daganatos betegs\u00e9gek vil\u00e1gszerte a hal\u00e1loz\u00e1s \u00e9s a tart\u00f3s\n                    eg\u00e9szs\u00e9groml\u00e1s vezet\u0151 okai k\u00f6z\u00e9 tartoznak, incidenci\u00e1juk a demogr\u00e1fiai \u00e9s\n                    \u00e9letm\u00f3dbeli v\u00e1ltoz\u00e1sok miatt tart\u00f3s emelked\u00e9st mutat. Az eml\u0151r\u00e1k a n\u0151k\n                    leggyakoribb rosszindulat\u00fa daganata. B\u00e1r a sz\u0171r\u00e9s, a korszer\u0171 immun-, c\u00e9lzott,\n                    HER2-ellenes biol\u00f3giai \u00e9s endokrin ter\u00e1pi\u00e1s kezel\u00e9sek, valamint az\n                    onkoplasztikai seb\u00e9szet jelent\u0151sen jav\u00edtotta a t\u00fal\u00e9l\u00e9si es\u00e9lyeket, mindez azzal\n                    is egy\u00fctt j\u00e1rt, hogy egyre t\u00f6bb beteg \u00e9l hossz\u00fa t\u00e1v\u00fa mell\u00e9khat\u00e1sokkal \u00e9s\n                    pszichoszoci\u00e1lis terhekkel. Ez a helyzet tette nyilv\u00e1nval\u00f3v\u00e1, hogy az onkol\u00f3giai\n                    ell\u00e1t\u00e1s siker\u00e9t nem lehet kiz\u00e1r\u00f3lag klasszikus v\u00e9gpontokkal \u2013 mint p\u00e9ld\u00e1ul a\n                    teljes, a betegs\u00e9gmentes \u00e9s a progresszi\u00f3mentes t\u00fal\u00e9l\u00e9s \u2013 m\u00e9rni. Az eg\u00e9szs\u00e9ggel\n                    \u00f6sszef\u00fcgg\u0151 \u00e9letmin\u0151s\u00e9g (HRQoL) olyan t\u00f6bbdimenzi\u00f3s konstrukci\u00f3, amely a fizikai\n                    t\u00fcnetterhel\u00e9st, a pszich\u00e9s \u00e1llapotot, a szoci\u00e1lis \u00e9s szerepfunkci\u00f3kat, valamint\n                    a funkcion\u00e1lis auton\u00f3mi\u00e1t egyar\u00e1nt figyelembe veszi. Eml\u0151r\u00e1kban ez kieg\u00e9sz\u00fcl\n                    tov\u00e1bb\u00e1 a testk\u00e9p, a szexu\u00e1lis funkci\u00f3 \u00e9s a n\u0151i identit\u00e1s k\u00e9rd\u00e9s\u00e9vel is. A HRQoL\n                    m\u00e9r\u00e9se valid\u00e1lt eszk\u00f6z\u00f6kre t\u00e1maszkodik, p\u00e9ld\u00e1ul az EORTC-QLQ-C30 k\u00e9rd\u0151\u00edvre \u00e9s az\n                    ehhez tartoz\u00f3 eml\u0151r\u00e1k-specifikus modulra (EORTC-QLQ-BR23), valamint a\n                    FACT-rendszerre (FACT-G, FACT-B). Sz\u00e1mos nagy mint\u00e1j\u00fa, egy\u00e9ni betegadatokon\n                    alapul\u00f3 metaanal\u00edzis igazolta, hogy a kiindul\u00e1si HRQoL-pontsz\u00e1mok \u00f6n\u00e1ll\u00f3\n                    prognosztikai jelent\u0151s\u00e9ggel b\u00edrnak a t\u00fal\u00e9l\u00e9s szempontj\u00e1b\u00f3l, m\u00e9g a tumorst\u00e1dium\n                    \u00e9s egy\u00e9b klinikopatol\u00f3giai t\u00e9nyez\u0151k kontroll\u00e1l\u00e1sa ut\u00e1n is. A HRQoL klinikai\n                    \u00e9rtelmez\u00e9s\u00e9t ugyanakkor t\u00f6bb t\u00e9nyez\u0151 is megnehez\u00edti: a m\u00e9r\u00e9s szubjekt\u00edv jellege,\n                    a v\u00e1laszad\u00e1si torz\u00edt\u00e1s, a betegs\u00e9g el\u0151rehalad\u00e1s\u00e1val egy\u00fctt j\u00e1r\u00f3 kognit\u00edv \u00e9s\n                    fizikai korl\u00e1tok, a \u2019response shift\u2019 jelens\u00e9ge, valamint a minim\u00e1lisan\n                    klinikailag jelent\u0151s k\u00fcl\u00f6nbs\u00e9g heterog\u00e9n meghat\u00e1roz\u00e1sa. Emellett a betegek\n                    v\u00e9gzetts\u00e9gi szintje \u00e9s eg\u00e9szs\u00e9g\u00e9rt\u00e9si k\u00e9pess\u00e9gei szint\u00e9n befoly\u00e1solhatj\u00e1k a\n                    k\u00e9rd\u0151\u00edvek megb\u00edzhat\u00f3 kit\u00f6lt\u00e9s\u00e9t. A jelen \u00e1ttekint\u00e9s c\u00e9lja, hogy rendszerezze a\n                    daganatos \u2013 k\u00fcl\u00f6n\u00f6sen az eml\u0151r\u00e1kos \u2013 betegek \u00e9letmin\u0151s\u00e9g-m\u00e9r\u00e9s\u00e9nek fogalmi,\n                    m\u00f3dszertani \u00e9s klinikai vonatkoz\u00e1sait, bemutassa a leggyakrabban haszn\u00e1lt\n                    m\u00e9r\u0151eszk\u00f6z\u00f6ket, \u00e9s r\u00e1vil\u00e1g\u00edtson arra, hogy a HRQoL mi\u00e9rt tekinthet\u0151 ma m\u00e1r\n                    nemcsak betegszempont\u00fa, hanem prognosztikus \u00e9s eg\u00e9szs\u00e9gpolitikai jelent\u0151s\u00e9g\u0171\n                    kimenetnek. Orv Hetil. 2026; 167(14): 530\u2013538.<\/jats:p>","DOI":"10.1556\/650.2026.33523","type":"journal-article","created":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T08:01:35Z","timestamp":1775376095000},"page":"530-538","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["Az \u00e9letmin\u0151s\u00e9g m\u00e9r\u00e9se eml\u0151daganatos betegek k\u00f6r\u00e9ben"],"prefix":"10.1556","volume":"167","author":[{"given":"Em\u0151ke","family":"Martinek","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika, Onkol\u00f3giai Profil Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Szekeres","sequence":"additional","affiliation":[{"name":"Orsz\u00e1gos Onkol\u00f3giai Int\u00e9zet Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-4889","authenticated-orcid":true,"given":"Zolt\u00e1n","family":"Herold","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika, Onkol\u00f3giai Profil Budapest Magyarorsz\u00e1g"},{"name":"Orsz\u00e1gos Onkol\u00f3giai Int\u00e9zet Budapest Magyarorsz\u00e1g"},{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai Onkol\u00f3giai Tansz\u00e9k Budapest, Baross u 23\u201325., 1082 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022:\n                    GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185\n                    countries. CA Cancer J Clin. 2024; 74: 229-263.\n                        https:\/\/doi.org\/10.3322\/caac.21834","DOI":"10.3322\/caac.21834"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Ott JJ, Ullrich A, Mascarenhas M, et al. Global cancer incidence and\n                    mortality caused by behavior and infection. J Public Health (Oxf). 2011; 33:\n                    223-233. https:\/\/doi.org\/10.1093\/pubmed\/fdq076","DOI":"10.1093\/pubmed\/fdq076"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012.\n                    CA Cancer J Clin. 2015; 65: 87-108.\n                        https:\/\/doi.org\/10.3322\/caac.21262","DOI":"10.3322\/caac.21262"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Barzaman K, Karami J, Zarei Z, et al. Breast cancer: Biology,\n                    biomarkers, and treatments. Int Immunopharmacol. 2020; 84: 106535.\n                        https:\/\/doi.org\/10.1016\/j.intimp.2020.106535","DOI":"10.1016\/j.intimp.2020.106535"},{"key":"R5","unstructured":"National Institute of Oncology. National Cancer Registry: Cancer\n                    statistics reports for Hungary. Available from: http:\/\/stat.nrr.hu\/\n                    [accessed: January 15, 2026]."},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Kenessey I, Szil\u00e1gyi I, Dobozi M, et al. The role of National Cancer\n                    Registry in the assessment of Hungarian cancer epidemiology. [A Nemzeti\n                    R\u00e1kregiszter szerepe a hazai daganatos epidemiol\u00f3giai helyzet felm\u00e9r\u00e9s\u00e9ben.] Orv\n                    Hetil. 2024; 165: 925-932. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2024.33062","DOI":"10.1556\/650.2024.33062"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Harbeck N, Gnant M. Breast cancer. Lancet 2017; 389: 1134-1150.\n                        https:\/\/doi.org\/10.1016\/S0140-6736(16)31891-8","DOI":"10.1016\/S0140-6736(16)31891-8"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Zielonke N, Gini A, Jansen EE, et al. Evidence for reducing\n                    cancer-specific mortality due to screening for breast cancer in Europe: a\n                    systematic review. Eur J Cancer 2020; 127: 191-206.\n                        https:\/\/doi.org\/10.1016\/j.ejca.2019.12.010","DOI":"10.1016\/j.ejca.2019.12.010"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Giordano L, von Karsa L, Tomatis M, et al. Mammographic screening\n                    programmes in Europe: organization, coverage and participation. J Med Screen.\n                    2012; 19(Suppl 1): 72-82.\n                    https:\/\/doi.org\/10.1258\/jms.2012.012085","DOI":"10.1258\/jms.2012.012085"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Belicza E, Surj\u00e1n C, Dombr\u00e1di V, et al. The effectiveness of the\n                    Hungarian mammography screening program. [A hazai mammogr\u00e1fi\u00e1s sz\u0171r\u0151program\n                    eredm\u00e9nyess\u00e9ge.] Orv Hetil. 2025; 166: 1689-1705. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2025.33400","DOI":"10.1556\/650.2025.33400"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Bostany G, Chen Y, Francisco L, et al. Cardiac dysfunction among\n                    breast cancer survivors: role of cardiotoxic therapy and cardiovascular risk\n                    factors. J Clin Oncol. 2025; 43: 32-45.\n                        https:\/\/doi.org\/10.1200\/JCO.23.01779","DOI":"10.1200\/JCO.23.01779"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Haidinger R, Bauerfeind I. Long-term side effects of adjuvant\n                    therapy in primary breast cancer patients: results of a web-based survey. Breast\n                    Care (Basel) 2019; 14: 111-116.\n                    https:\/\/doi.org\/10.1159\/000497233","DOI":"10.1159\/000497233"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Horv\u00e1th A, R\u00e9dling M. Breast cancer-related lymphedema and\n                    treatment. [Eml\u0151tumorhoz t\u00e1rsul\u00f3 lymphoedema \u00e9s kezel\u00e9se.] Orv Hetil. 2022; 163:\n                    902-910. [Hungarian]\n                    https:\/\/doi.org\/10.1556\/650.2022.32468","DOI":"10.1556\/650.2022.32468"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Groenvold M, Klee MC, Sprangers MA, et al. Validation of the EORTC\n                    QLQ-C30 quality of life questionnaire through combined qualitative and\n                    quantitative assessment of patient-observer agreement. J Clin Epidemiol. 1997;\n                    50: 441-450.\n                    https:\/\/doi.org\/10.1016\/S0895-4356(96)00428-3","DOI":"10.1016\/S0895-4356(96)00428-3"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Cella DF, Tulsky DS, Gray G, et al. The functional assessment of\n                    cancer therapy scale: development and validation of the general measure. J Clin\n                    Oncol. 1993; 11: 570-579.\n                    https:\/\/doi.org\/10.1200\/JCO.1993.11.3.570","DOI":"10.1200\/JCO.1993.11.3.570"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a\n                    prognostic indicator of survival: a meta-analysis of individual patient data\n                    from EORTC clinical trials. Lancet Oncol. 2009; 10: 865-871.\n                        https:\/\/doi.org\/10.1016\/S1470-2045(09)70200-1","DOI":"10.1016\/S1470-2045(09)70200-1"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Ediebah DE, Quinten C, Coens C, et al. Quality of life as a\n                    prognostic indicator of survival: A pooled analysis of individual patient data\n                    from Canadian cancer trials group clinical trials. Cancer 2018; 124: 3409-3416.\n                        https:\/\/doi.org\/10.1002\/cncr.31556","DOI":"10.1002\/cncr.31556"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Sprangers MA, Groenvold M, Arraras JI, et al. The European\n                    Organization for Research and Treatment of Cancer breast cancer-specific\n                    quality-of-life questionnaire module: first results from a three-country field\n                    study. J Clin Oncol. 1996; 14: 2756-2768.\n                        https:\/\/doi.org\/10.1200\/JCO.1996.14.10.2756","DOI":"10.1200\/JCO.1996.14.10.2756"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Pirl WF, Fann JR, Greer JA, et al. Recommendations for the\n                    implementation of distress screening programs in cancer centers: report from the\n                    American Psychosocial Oncology Society (APOS), Association of Oncology Social\n                    Work (AOSW), and Oncology Nursing Society (ONS) joint task force. Cancer 2014;\n                    120: 2946-2954. https:\/\/doi.org\/10.1002\/cncr.28750","DOI":"10.1002\/cncr.28750"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Holland JC, Bultz BD, National Comprehensive Cancer Network (NCCN).\n                    The NCCN guideline for distress management: a case for making distress the sixth\n                    vital sign. J Natl Compr Canc Netw. 2007; 5: 3-7.\n                        https:\/\/doi.org\/10.6004\/jnccn.2007.0003","DOI":"10.6004\/jnccn.2007.0003"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"The WHOQOL Group. Development of the World Health Organization\n                    WHOQOL-BREF quality of life assessment. Psychol Med. 1998; 28: 551-558.\n                        https:\/\/doi.org\/10.1017\/S0033291798006667","DOI":"10.1017\/S0033291798006667"},{"key":"R22","unstructured":"World Health Organization. WHOQOL: Measuring quality of life.\n                    Available from: https:\/\/www.who.int\/tools\/whoqol [accessed: November\n                    10, 2025]."},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Karimi M, Brazier J. Health, health-related quality of life, and\n                    quality of life: what is the difference? Pharmacoeconomics 2016; 34: 645-649.\n                        https:\/\/doi.org\/10.1007\/s40273-016-0389-9","DOI":"10.1007\/s40273-016-0389-9"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Zang Y, Qiu Y, Sun Y, et al. Baseline functioning scales of EORTC\n                    QLQ-C30 predict overall survival in patients with gastrointestinal cancer: a\n                    meta-analysis. Qual Life Res. 2024; 33: 1455-1468.\n                        https:\/\/doi.org\/10.1007\/s11136-023-03591-y","DOI":"10.1007\/s11136-023-03591-y"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Panzini RG, Mosqueiro BP, Zimpel RR, et al. Quality-of-life and\n                    spirituality. Int Rev Psychiatry 2017; 29: 263-282.\n                        https:\/\/doi.org\/10.1080\/09540261.2017.1285553","DOI":"10.1080\/09540261.2017.1285553"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Ganz PA, Rowland JH, Desmond K, et al. Life after breast cancer:\n                    understanding women\u2019s health-related quality of life and sexual functioning. J\n                    Clin Oncol. 1998; 16: 501-514.\n                        https:\/\/doi.org\/10.1200\/JCO.1998.16.2.501","DOI":"10.1200\/JCO.1998.16.2.501"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer\n                    survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol.\n                    2000; 18: 743-753.\n                    https:\/\/doi.org\/10.1200\/JCO.2000.18.4.743","DOI":"10.1200\/JCO.2000.18.4.743"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Bollmann AK, F\u00e1bi\u00e1n B, Moln\u00e1r J. Investigation of sleep and fatigue\n                    in patients with cancer. [Az alv\u00e1s \u00e9s a kimer\u00fclts\u00e9g vizsg\u00e1lata daganatos betegek\n                    k\u00f6r\u00e9ben.] Orv Hetil. 2018; 159: 1720-1726. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2018.31154","DOI":"10.1556\/650.2018.31154"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"D\u00e9sfalvi J, Lakatos C, Csuka SI, et al. Attachment style,\n                    relationship and sexual satisfaction: comparing breast cancer patients and\n                    healthy women. [K\u00f6t\u0151d\u00e9si st\u00edlus, kapcsolati \u00e9s szexu\u00e1lis el\u00e9gedetts\u00e9g: eml\u0151r\u00e1kos\n                    \u00e9s eg\u00e9szs\u00e9ges n\u0151k \u00f6sszehasonl\u00edt\u00f3 vizsg\u00e1lata.] Orv Hetil. 2020; 161: 510-518.\n                    [Hungarian] https:\/\/doi.org\/10.1556\/650.2020.31686","DOI":"10.1556\/650.2020.31686"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Cocks K, Wells JR, Johnson C, et al. Content validity of the EORTC\n                    quality of life questionnaire QLQ-C30 for use in cancer. Eur J Cancer 2023; 178:\n                    128-138. https:\/\/doi.org\/10.1016\/j.ejca.2022.10.026","DOI":"10.1016\/j.ejca.2022.10.026"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Ware JE Jr., Gandek B. Overview of the SF-36 health survey and the\n                    International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol.\n                    1998; 51: 903-912.\n                    https:\/\/doi.org\/10.1016\/S0895-4356(98)00081-X","DOI":"10.1016\/S0895-4356(98)00081-X"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"EuroQol Group. EuroQol - a new facility for the measurement of\n                    health-related quality of life. Health Policy 1990; 16: 199-208.\n                        https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"R33","unstructured":"M\u00f3nok K, Kov\u00e1cs Z, Rig\u00f3 A, et al. Psychometric properties of the\n                    Hungarian version of the EORTC QLQ-BR23. [Az EORTC QLQ-BR23 magyar v\u00e1ltozat\u00e1nak\n                    pszichometriai jellemz\u0151i.] Alk Pszichol. 2013; 14: 45-58.\n                    [Hungarian]"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Mah K, Swami N, Le LW, et al. Validation of the 7-item functional\n                    assessment of cancer therapy-general (FACT-G7) as a short measure of quality of\n                    life in patients with advanced cancer. Cancer 2020; 126: 3750-3757.\n                        https:\/\/doi.org\/10.1002\/cncr.32981","DOI":"10.1002\/cncr.32981"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance\n                    of changes in health-related quality-of-life scores. J Clin Oncol. 1998; 16:\n                    139-144. https:\/\/doi.org\/10.1200\/JCO.1998.16.1.139","DOI":"10.1200\/JCO.1998.16.1.139"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Basch E, Deal AM, Kris MG, et al. Symptom monitoring with\n                    patient-reported outcomes during routine cancer treatment: a randomized\n                    controlled trial. J Clin Oncol. 2016; 34: 557-565. Erratum: J Clin Oncol. 2016;\n                    34: 2198. Erratum: J Clin Oncol. 2019: 37: 528.\n                        https:\/\/doi.org\/10.1200\/JCO.2015.63.0830","DOI":"10.1200\/JCO.2015.63.0830"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez-Pardo S, De Paz JA, Montserrat Romero-Perez E, et al.\n                    Factors associated with body image and self-esteem in mastectomized breast\n                    cancer survivors. Int J Environ Res Public Health 2023; 20: 5154,\n                        https:\/\/doi.org\/10.3390\/ijerph20065154","DOI":"10.3390\/ijerph20065154"},{"key":"R38","unstructured":"National Institute for Health and Care Excellence. Depression in\n                    adults: treatment and management. NICE guideline. Published: 29 June 2022.\n                    Available from: https:\/\/www.nice.org.uk\/guidance\/ng222 [accessed:\n                    Decmber 15, 2025]."},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Moorey S, Watson M. Cognitive therapy. In: Holland JC, Breitbart WS,\n                    Jacobsen PB, et al. (ed.) Psycho-oncology. 3rd ed. Oxford University Press,\n                    Oxford, 2015; pp. 402-407.\n                        https:\/\/doi.org\/10.1093\/med\/9780195367430.003.0054","DOI":"10.1093\/med\/9780195367430.003.0054"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Sprangers MA, Schwartz CE. Integrating response shift into\n                    health-related quality of life research: a theoretical model. Soc Sci Med. 1999;\n                    48: 1507-1515.\n                    https:\/\/doi.org\/10.1016\/S0277-9536(99)00045-3","DOI":"10.1016\/S0277-9536(99)00045-3"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Basch E, Deal AM, Dueck AC, et al. Overall survival results of a\n                    trial assessing patient-reported outcomes for symptom monitoring during routine\n                    cancer treatment. JAMA 2017; 318: 197-198.\n                        https:\/\/doi.org\/10.1001\/jama.2017.7156","DOI":"10.1001\/jama.2017.7156"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Greenhalgh T, Wherton J, Papoutsi C, et al. Beyond adoption: a new\n                    framework for theorizing and evaluating nonadoption, abandonment, and challenges\n                    to the scale-up, spread, and sustainability of health and care technologies. J\n                    Med Internet Res. 2017; 19: e367.\n                    https:\/\/doi.org\/10.2196\/jmir.8775","DOI":"10.2196\/jmir.8775"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"Snyder CF, Aaronson NK, Choucair AK, et al. Implementing\n                    patient-reported outcomes assessment in clinical practice: a review of the\n                    options and considerations. Qual Life Res. 2012; 21: 1305-1314.\n                        https:\/\/doi.org\/10.1007\/s11136-011-0054-x","DOI":"10.1007\/s11136-011-0054-x"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/14\/article-p530.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/14\/article-p530.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/14\/article-p530.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:20:09Z","timestamp":1785500409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/14\/article-p530.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,5]]},"references-count":43,"journal-issue":{"issue":"14"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33523","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,5]]}}}